Secondary Logo

Journal Logo

Abstracts: SUBMITTED, NOT PRESENTED: STOMACH

Study of Incidence of Gastric Cancer After H. pylori Eradication in Patients With Long-Term Administration of Low-Dose Aspirin

2893

Takahashi, Koji MD1; Kawai, Takashi MD, PhD, FACG1; Aoki, Yuki MD1; Sugimoto, Akihiko MD1; Takahashi, Shin'ichi Jr. MD, FACG2

Author Information
American Journal of Gastroenterology: October 2018 - Volume 113 - Issue - p S1595
  • Free

Introduction: We investigated incidence of gastric cancer after H.pylori eradication in patients with long-term administration of low-dose aspirin (LDA).

Methods: The subjects were 101 consecutive outpatients attending the Cardiovascular Department and who had been on LDA therapy for at least 3 months from February 2007 to December 2008. Average age was 67.2 ± 8.3, male/ female ratio was 3.8:1. Firstly all patients were conducted esophagogastroduodenoscopy (EGD) and 13C- Urea breath test. H.pyloripositive patients were received eradication treatment. After eradication all patients were received periodic EGD.

Results:H.pylori positive was 55cases and negative 46 cases. We detected 4 cases early gastric cancer, detection rate was very high (3.96%). All gastric cancer patients were H.pyloripositive and advanced endoscopic atrophy. We performed H.pylori eradication 41 cases. Afterword we detected 3 cases early gastric cancer, detection rate was also high (6.52%). Interestingly the periods from eradication of H.pylori to detection of gastric cancer was longer (average: 80 month) than that of previous reports in non-LDA users (within 60 month). Total taking LDA period was also very long (average: 184 month).

Conclusion: LDA does not prevent from incidence of gastric cancer after H.pylorieradication. But it is possible that taking LDA delay the growth of gastric cancer after H.pylori eradication.

© The American College of Gastroenterology 2018. All Rights Reserved.